Dupilumab for the treatment of atopic dermatitis of the elderly: a real-life 52-week experience

J Dermatolog Treat. 2023 Dec;34(1):2192840. doi: 10.1080/09546634.2023.2192840.

Authors

Luigi Gargiulo^{1

2}, Francesco Piscazzi^{1

2}, Luciano Ibba^{1

2}, Mario Valenti^{1

2}, Paola Facheris², Chiara Perugini², Antonio Costanzo^{1

2}, Alessandra Narcisi²

Affiliations

¹ Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.
² Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy.

PMID: 36927393
DOI: 10.1080/09546634.2023.2192840

No abstract available

MeSH terms

Aged
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Dermatitis, Atopic*
Humans
Severity of Illness Index
Treatment Outcome

Substances

dupilumab
Antibodies, Monoclonal, Humanized
Antibodies, Monoclonal